{"id":"drofenine","rwe":[{"pmid":"41184693","year":"2025","title":"Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K(+) voltage-dependent Kv2.1 channel.","finding":"","journal":"Journal of physiology and biochemistry","studyType":"Clinical Study"},{"pmid":"40041886","year":"2025","title":"Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through Aβ/Kv2.1/microglial NLRP3/neuronal Tau axis.","finding":"","journal":"Acta pharmaceutica Sinica. B","studyType":"Clinical Study"},{"pmid":"33906111","year":"2021","title":"Inhibition of the transient receptor potential vanilloid 3 channel attenuates carbon tetrachloride-induced hepatic fibrosis.","finding":"","journal":"Biochemical and biophysical research communications","studyType":"Clinical Study"},{"pmid":"33089105","year":"2020","title":"Antispasmodic Drug Drofenine as an Inhibitor of Kv2.1 Channel Ameliorates Peripheral Neuropathy in Diabetic Mice.","finding":"","journal":"iScience","studyType":"Clinical Study"},{"pmid":"25089200","year":"2014","title":"Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3.","finding":"","journal":"Pharmacology research & perspectives","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cyclovegantine","offLabel":[],"synonyms":["drofenine","drofenine hydrochloride","cycloadiphenine","cycloadiphenine hydrochloride","hexahydroadiphenine hydrochloride","hexahydroadiphenine","cyclovegantine","drofenine HCl","cycloadiphenine HCl","hexahydroadiphenine HCl"],"timeline":[],"approvals":[],"brandName":"Cyclovegantine","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like locks, and Cyclovexgantine is a key that fits into those locks. When it binds to the right lock, it can help to turn off or turn on certain cellular processes that are involved in the disease it's being used to treat. This can help to restore balance to the body's normal functioning.","oneSentence":"Cyclovexgantine works by binding to specific proteins or receptors in the body to produce a therapeutic effect.","technicalDetail":"Cyclovexgantine's exact mechanism of action is unknown, but as a small molecule, it is likely to work through a combination of receptor binding and modulation of downstream signaling pathways."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4963","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DROFENINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T10:53:18.466278","biosimilars":[],"competitors":[],"genericName":"drofenine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006065","UNII":"4QWV355536","CHEBI":"CHEBI:93825","INN_ID":"3105","RXNORM":"21945","UMLSCUI":"C0056727","ChEMBL_ID":"CHEMBL442444","PUBCHEM_CID":"3166","SNOMEDCT_US":"19261000122107","SECONDARY_CAS_RN":"548-66-3","MESH_SUPPLEMENTAL_RECORD_UI":"C007183"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":7,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov","pmid":"41184693","title":"Inhibition of cancerous properties of triple-negative MDA-MB-436 cells by targeting the K(+) voltage-dependent Kv2.1 channel.","journal":"Journal of physiology and biochemistry"},{"date":"2025 Jan","pmid":"40041886","title":"Drofenine as a Kv2.1 inhibitor alleviated AD-like pathology in mice through Aβ/Kv2.1/microglial NLRP3/neuronal Tau axis.","journal":"Acta pharmaceutica Sinica. B"},{"date":"2021 Jun 18","pmid":"33906111","title":"Inhibition of the transient receptor potential vanilloid 3 channel attenuates carbon tetrachloride-induced hepatic fibrosis.","journal":"Biochemical and biophysical research communications"},{"date":"2020 Oct 23","pmid":"33089105","title":"Antispasmodic Drug Drofenine as an Inhibitor of Kv2.1 Channel Ameliorates Peripheral Neuropathy in Diabetic Mice.","journal":"iScience"},{"date":"2014 Oct","pmid":"25089200","title":"Drofenine: A 2-APB Analogue with Greater Selectivity for Human TRPV3.","journal":"Pharmacology research & perspectives"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cyclovexgantine, also known as DROFENINE, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Cyclovexgantine are also unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further research is needed to fully understand its mechanism of action and safety profile.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}